Generated by Meeveem AI
"Pioneering genetic medicine to transform treatment for rare and common diseases"
MeiraGTx develops gene therapies that address both inherited retinal diseases and widespread conditions like Parkinson's disease and metabolic disorders. The company combines cutting edge viral vector design with proprietary riboswitch technology, enabling precise, controllable gene expression through oral medication. This flexibility expands genetic medicine beyond traditional applications. MeiraGTx operates end to end in house GMP manufacturing across facilities in the US, UK, and Ireland, ensuring quality control from vector design through clinical production. Each therapy targets specific patient needs, from restoring sight in children with congenital blindness to managing chronic neurological and metabolic conditions in adults.
381
Team Members
2015
Founded
Biotechnology
Sector
On-Site
Work Environment
A world where genetic medicine offers curative solutions for any disease, inherited or acquired, with precision and control that matches each patient's unique biology.
MeiraGTx develops innovative gene therapies to improve the lives of patients with serious diseases.